These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 30797495)

  • 1. Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report.
    Tunali I; Gray JE; Qi J; Abdalah M; Jeong DK; Guvenis A; Gillies RJ; Schabath MB
    Lung Cancer; 2019 Mar; 129():75-79. PubMed ID: 30797495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer.
    Yang B; Zhou L; Zhong J; Lv T; Li A; Ma L; Zhong J; Yin S; Huang L; Zhou C; Li X; Ge YQ; Tao X; Zhang L; Son Y; Lu G
    Respir Res; 2021 Jun; 22(1):189. PubMed ID: 34183009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade.
    Vaidya P; Bera K; Patil PD; Gupta A; Jain P; Alilou M; Khorrami M; Velcheti V; Madabhushi A
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33051342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The NSCLC immunotherapy response predicted by tumor-infiltrating T cells via a non-invasive radiomic approach.
    Min J; Dong F; Chen Y; Li W; Wu Y; Tan Y; Yang F; Wu P; Chai Y
    Front Immunol; 2024; 15():1379812. PubMed ID: 39315096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrative nomogram of CT imaging, clinical, and hematological features for survival prediction of patients with locally advanced non-small cell lung cancer.
    Wang L; Dong T; Xin B; Xu C; Guo M; Zhang H; Feng D; Wang X; Yu J
    Eur Radiol; 2019 Jun; 29(6):2958-2967. PubMed ID: 30643940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of a Radiomic Signature Developed in a General NSCLC Cohort for Predicting Overall Survival of ALK-Positive Patients With Different Treatment Types.
    Huang L; Chen J; Hu W; Xu X; Liu D; Wen J; Lu J; Cao J; Zhang J; Gu Y; Wang J; Fan M
    Clin Lung Cancer; 2019 Nov; 20(6):e638-e651. PubMed ID: 31375452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical multi-dimensional prognostic nomogram for predicting the efficacy of immunotherapy in NSCLC.
    Zhao Q; Zhong X; Wang X; Li B; Xu Y; Yu J; Wang L
    Sci Rep; 2024 Sep; 14(1):21380. PubMed ID: 39271765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pre-treatment CT-based weighted radiomic approach combined with clinical characteristics to predict durable clinical benefits of immunotherapy in advanced lung cancer.
    Zhu Z; Chen M; Hu G; Pan Z; Han W; Tan W; Zhou Z; Wang M; Mao L; Li X; Sui X; Song L; Xu Y; Song W; Yu Y; Jin Z
    Eur Radiol; 2023 Jun; 33(6):3918-3930. PubMed ID: 36515714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A short-term follow-up CT based radiomics approach to predict response to immunotherapy in advanced non-small-cell lung cancer.
    Gong J; Bao X; Wang T; Liu J; Peng W; Shi J; Wu F; Gu Y
    Oncoimmunology; 2022; 11(1):2028962. PubMed ID: 35096486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential CT Findings in Patients With Non-small-cell Lung Cancer Receiving Nivolumab.
    Johnson DY; Short RG; Patz EF
    Clin Lung Cancer; 2018 Mar; 19(2):175-180. PubMed ID: 29153896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-Related Radiomics and Immunotherapy Response: A Multicohort Study of Non-Small Cell Lung Cancer.
    Tunali I; Tan Y; Gray JE; Katsoulakis E; Eschrich SA; Saller J; Aerts HJWL; Boyle T; Qi J; Guvenis A; Gillies RJ; Schabath MB
    JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34409252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of an MRI-Based nomogram to predict the effectiveness of immunotherapy for brain metastasis in patients with non-small cell lung cancer.
    Xu J; Wang P; Li Y; Shi X; Yin T; Yu J; Teng F
    Front Immunol; 2024; 15():1373330. PubMed ID: 38686383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition.
    Li Y; Wang P; Xu J; Shi X; Yin T; Teng F
    Oncoimmunology; 2024; 13(1):2312628. PubMed ID: 38343749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized prediction of immunotherapy response in lung cancer patients using advanced radiomics and deep learning.
    Liao CY; Chen YM; Wu YT; Chao HS; Chiu HY; Wang TW; Chen JR; Shiao TH; Lu CF
    Cancer Imaging; 2024 Sep; 24(1):129. PubMed ID: 39350284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel machine learning model for efficacy prediction of immunotherapy-chemotherapy in NSCLC based on CT radiomics.
    Li C; Zhou Z; Hou L; Hu K; Wu Z; Xie Y; Ouyang J; Cai X
    Comput Biol Med; 2024 Aug; 178():108638. PubMed ID: 38897152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applications of CT-based radiomics for the prediction of immune checkpoint markers and immunotherapeutic outcomes in non-small cell lung cancer.
    Zheng J; Xu S; Wang G; Shi Y
    Front Immunol; 2024; 15():1434171. PubMed ID: 39238640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Radiomic-Based Model to Predict Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.
    Tankyevych O; Trousset F; Latappy C; Berraho M; Dutilh J; Tasu JP; Lamour C; Cheze Le Rest C
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CT-based radiomic analysis of stereotactic body radiation therapy patients with lung cancer.
    Huynh E; Coroller TP; Narayan V; Agrawal V; Hou Y; Romano J; Franco I; Mak RH; Aerts HJ
    Radiother Oncol; 2016 Aug; 120(2):258-66. PubMed ID: 27296412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.
    Maymani H; Hess K; Groisberg R; Hong DS; Naing A; Piha-Paul S; Janku F; Fu S; Tsimberidou AM; Pant S; Karp D; Liu S; Sun M; Heymach J; Simon G; Meric-Bernstam F; Subbiah V
    Lung Cancer; 2018 Jun; 120():137-141. PubMed ID: 29748008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.